Login to Your Account

Other News To Note

Wednesday, July 25, 2012
• Camargo Pharmaceutical Services, of Cincinnati, said it completed five pre-investigational new drug meetings last month with the FDA for 505(b)(2) products, including two for India-based pharmaceutical companies. Since 505(b)(2) drugs rely in part on data from already approved therapies, they can be developed and get FDA approval in as little as 30 months with fewer trials and at a lower cost.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription